Clinical trials · Virginia
High Grade Serous Ovarian Cancer clinical trials in Virginia
We’re tracking 27 recruiting high grade serous ovarian cancer studies with a site in Virginia — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Virginia
- NCT07318558RecruitingPhase 3
Study of Sac-TMT for advanced ovarian cancer without HRD
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
Fairfax, VirginiaAges 18 years+ - NCT06799065RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.
Fairfax, VirginiaAges 18 years+ - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Charlottesville, VirginiaAges 18 years+ - NCT06580314RecruitingPhase 3
Olaparib with or without bevacizumab for ovarian cancer
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
Charlottesville, VirginiaAges 18 years+ - NCT06072781RecruitingPhase 3
Study of Avutometinib + Defactinib for recurrent low-grade ovarian cancer
This trial tests a combination of two oral targeted drugs for people with recurrent low-grade serous ovarian cancer. It aims to see if this therapy works better than standard hormone therapy or chemotherapy options.
Charlottesville, VirginiaAges 18 years+ - NCT04633239RecruitingPhase 1
Testing abemaciclib plus olaparib for recurrent ovarian cancer
This Phase 1 trial studies whether adding abemaciclib to olaparib can treat women with recurrent platinum-resistant ovarian cancer. It aims to find a safe dose and see how well the combination can control the cancer.
Charlottesville, VirginiaAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Fairfax, VirginiaAges 18 years+ - NCT06161025RecruitingPhase 2/Phase 3
Raludotatug Deruxtecan for resistant ovarian cancer
This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.
Charlottesville, VirginiaAges 18 years+ - NCT07278336RecruitingPhase 1
Study of ABBV901 for ovarian cancer
This trial tests a new drug called ABBV901, given alone or with another drug (bevacizumab), for people with a certain type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if it helps control the disease.
Fairfax, VirginiaAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Fairfax, VirginiaAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Fairfax, VirginiaAges 18 years+ - NCT05659381RecruitingPhase 3
Heated belly chemo plus niraparib after interval surgery for ovarian cancer
This Phase 3 study tests whether heated chemotherapy placed inside the belly, followed by interval surgery and the maintenance medicine niraparib, can improve outcomes for certain advanced ovarian, fallopian tube, or primary peritoneal cancers. It focuses on people whose tumors are HRD/LOH positive and who can have all visible disease removed.
Fairfax, VirginiaAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Fairfax, VirginiaAges 18 years+ - NCT06690775RecruitingPhase 2
Study of a new drug for platinum-resistant ovarian cancer
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Norfolk, VirginiaAges 18 years+ - NCT07115043RecruitingPhase 1/Phase 2
Study of AZD6750 for advanced solid tumors
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT05128825RecruitingPhase 2
Test drug azenosertib for platinum-resistant ovarian cancer
This Phase 2 trial tests azenosertib to treat platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. It looks for whether the drug can shrink tumors and improve outcomes in people whose cancer has returned after platinum chemotherapy.
Fairfax, VirginiaAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT07218809RecruitingPhase 3
Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
Fairfax, VirginiaAges 18 years+ - NCT05080946RecruitingEarly Phase 1
Aspirin with chemotherapy to improve ovarian tumor immune features
This early-phase study tests whether adding aspirin to standard neoadjuvant chemotherapy can change immune (anti-tumor) features inside ovarian, fallopian tube, or peritoneal tumors. It may help doctors better understand which patients respond and how aspirin could make treatment work better.
Charlottesville, VirginiaAges 18 years+ - NCT04315233RecruitingPhase 1
Testing two drugs for hard-to-treat triple-negative breast and ovarian cancer
This Phase 1 trial tests ribociclib plus belinostat in people with metastatic triple-negative breast cancer or recurrent ovarian cancer. It also looks at your tumor’s genetics (from a fresh biopsy) to see who might respond better.
Fairfax, VirginiaAges 18 years+ - NCT06843447RecruitingPhase 1/Phase 2
Study of Raludotatug Deruxtecan for Ovarian Cancer
This study tests a new drug called raludotatug deruxtecan for people with ovarian cancer that has come back. It's designed for those whose cancer is either sensitive or resistant to platinum chemotherapy, and who have had 1-3 prior treatments.
Charlottesville, VirginiaAges 18 years+ - NCT04606914RecruitingPhase 2
Carboplatin plus mirvetuximab for advanced ovarian cancer after chemo
This Phase 2 study tests adding mirvetuximab to carboplatin for people with advanced, high-grade serous ovarian cancer who will first receive “neoadjuvant” chemotherapy. It is designed for tumors that strongly show FRα, which mirvetuximab targets, to see if this improves outcomes.
Richmond, VirginiaAges 18 years+ - NCT07226427RecruitingPhase 1
Study of MEN2501 for platinum-resistant ovarian cancer
This trial tests a new drug called MEN2501 for people with ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if it is safe and if it can help shrink tumors.
Fairfax, VirginiaAges 18 years+ - NCT07214779RecruitingPhase 3
New drug vs chemo for platinum-resistant ovarian cancer
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Charlottesville, VirginiaAges 18 years+
Where these studies are running in Virginia
Institutions with a site for the recruiting high grade serous ovarian cancer studies listed above.
- Inova Schar Cancer Institute · 6 studies
- NEXT Oncology · 5 studies
- Virginia Cancer Specialists · 5 studies
- Virginia Oncology Associates · 5 studies
- University of Virginia Cancer Center · 4 studies
- Research Site · 2 studies
- University of Virginia · 2 studies
- University of Virginia Health System · 2 studies
What taking part in a high grade serous ovarian cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
High Grade Serous Ovarian Cancer trials in other states
Common questions
- Are there high grade serous ovarian cancer clinical trials in Virginia?
- Yes. We're currently tracking 27 recruiting high grade serous ovarian cancer studies with a site in Virginia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a high grade serous ovarian cancer study in Virginia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Virginia to take part?
- Not necessarily. These studies have a site in Virginia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a high grade serous ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New high grade serous ovarian cancer studies open in Virginia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.